Stem Cells: Japan Gets Ahead of the Curve
By Andreas Seibert,
Time
| 06. 15. 2007
Everything about Shinya Yamanaka's discovery was right-except for the timing. The 44-year-old Kyoto University stem-cell researcher had found a way to genetically reprogram an ordinary mouse skin cell to revert to the virtual equivalent of its embryonic state, in which it has the potential to grow into any kind of tissue. The finding was a promising first step toward the creation of stem-cell lines for near-miraculous medical treatments-and because Yamanaka did not use human embryos, his technique offered researchers everywhere a way to sidestep the ethical controversies that have dogged the field since its birth. But it was March 2006, just months after the South Korean stem-cell scientist Hwang Woo Suk-who had become an international sensation after claiming to have cloned a human embryo, a first-had been exposed as a fraud. As another Asian stem-cell scientist announcing a surprise advance, Yamanaka knew his peers would put him under the microscope. "I was very nervous," he recalls. A few weeks later at a scientific conference in Whistler, Canada, where he delivered his findings to an audience of international colleagues, "I could...
Related Articles
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...
By Roni Caryn Rabin, The New York Times | 01.22.2026
The National Institutes of Health said on Thursday it is ending support for all research that makes use of human fetal tissue, eliminating funding for projects both within and outside of the agency.
A ban instituted in June 2019 by...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...